Correction to: Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent

Zoltan Szucs¹, James Joseph^{1

2

3}, Tim J Larkin¹, Bangwen Xie¹, Sarah E Bohndiek^{1

2}, Kevin M Brindle^{4

5}, André A Neves⁶

Affiliations

¹ Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK.
² Department of Physics, University of Cambridge, Cambridge, UK.
³ Present address: School of Science and Engineering, University of Dundee, Dundee, UK.
⁴ Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK. kmb1001@cam.ac.uk.
⁵ Department of Biochemistry, University of Cambridge, Cambridge, UK. kmb1001@cam.ac.uk.
⁶ Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK. andre.neves@cruk.cam.ac.uk.

PMID: 33722249
PMCID: PMC7958420
DOI: 10.1186/s13058-021-01414-x

Published Erratum

Correction to: Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent

Zoltan Szucs et al. Breast Cancer Res. 2021.

. 2021 Mar 15;23(1):32.

doi: 10.1186/s13058-021-01414-x.

Authors

Zoltan Szucs¹, James Joseph^{1

2

3}, Tim J Larkin¹, Bangwen Xie¹, Sarah E Bohndiek^{1

2}, Kevin M Brindle^{4

5}, André A Neves⁶

Affiliations

¹ Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK.
² Department of Physics, University of Cambridge, Cambridge, UK.
³ Present address: School of Science and Engineering, University of Dundee, Dundee, UK.
⁴ Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK. kmb1001@cam.ac.uk.
⁵ Department of Biochemistry, University of Cambridge, Cambridge, UK. kmb1001@cam.ac.uk.
⁶ Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK. andre.neves@cruk.cam.ac.uk.

PMID: 33722249
PMCID: PMC7958420
DOI: 10.1186/s13058-021-01414-x

No abstract available

PubMed Disclaimer

Erratum for

Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent.
Szucs Z, Joseph J, Larkin TJ, Xie B, Bohndiek SE, Brindle KM, Neves AA. Szucs Z, et al. Breast Cancer Res. 2021 Feb 17;23(1):25. doi: 10.1186/s13058-021-01404-z. Breast Cancer Res. 2021. PMID: 33596961 Free PMC article.

Cited by

Improved Multimodal Tumor Necrosis Imaging with IRDye800CW-DOTA Conjugated to an Albumin-Binding Domain.
Stroet MCM, de Blois E, de Jong M, Seimbille Y, Mezzanotte L, Löwik CWGM, Panth KM. Stroet MCM, et al. Cancers (Basel). 2022 Feb 9;14(4):861. doi: 10.3390/cancers14040861. Cancers (Basel). 2022. PMID: 35205609 Free PMC article.

References

1. Szucs Z, et al. Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent. Breast Cancer Res. 2021;23:25. doi: 10.1186/s13058-021-01404-z. - DOI - PMC - PubMed

Publication types

Actions

Grants and funding

21142/CRUK_/Cancer Research UK/United Kingdom

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction to: Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent

Affiliations

Correction to: Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent

Authors

Affiliations

Erratum for

Similar articles

Cited by

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources